Organon & Co. (NYSE:OGN) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its position in shares of Organon & Co. (NYSE:OGN) by 46.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,784 shares of the company’s stock after selling 29,539 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Organon & Co. were worth $487,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. New York State Teachers Retirement System raised its holdings in Organon & Co. by 20.1% during the fourth quarter. New York State Teachers Retirement System now owns 348,226 shares of the company’s stock worth $5,021,000 after purchasing an additional 58,321 shares during the last quarter. State of Alaska Department of Revenue increased its position in Organon & Co. by 417.8% during the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company’s stock worth $2,267,000 after buying an additional 126,882 shares in the last quarter. UBS Group AG increased its position in Organon & Co. by 88.3% during the third quarter. UBS Group AG now owns 657,912 shares of the company’s stock worth $11,421,000 after buying an additional 308,470 shares in the last quarter. Nordea Investment Management AB increased its position in Organon & Co. by 2,016.0% during the fourth quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock worth $44,648,000 after buying an additional 2,980,945 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Organon & Co. by 29.7% during the third quarter. Deutsche Bank AG now owns 798,210 shares of the company’s stock worth $13,857,000 after buying an additional 182,822 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Kirke Weaver purchased 2,720 shares of the stock in a transaction on Thursday, February 22nd. The stock was purchased at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the transaction, the insider now owns 15,181 shares in the company, valued at $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.17% of the company’s stock.

Organon & Co. Stock Up 0.4 %

Shares of NYSE:OGN opened at $17.87 on Thursday. The company has a market cap of $4.57 billion, a P/E ratio of 4.47, a P/E/G ratio of 0.84 and a beta of 0.83. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $24.79. The business has a fifty day simple moving average of $17.96 and a 200-day simple moving average of $15.61.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. Sell-side analysts expect that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.27%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s dividend payout ratio is currently 28.00%.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.